148 related articles for article (PubMed ID: 28833354)
1. Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Simonitsch-Klupp I; Kornauth C; Dolak W; Lukas J; Mayerhoefer ME; Raderer M
Hematol Oncol; 2018 Feb; 36(1):62-67. PubMed ID: 28833354
[TBL] [Abstract][Full Text] [Related]
2. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
[TBL] [Abstract][Full Text] [Related]
3. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Troch M; Dolak W; Müllauer L; Lukas J; Zielinski CC; Raderer M
Haematologica; 2013 Mar; 98(3):353-6. PubMed ID: 22899582
[TBL] [Abstract][Full Text] [Related]
5. Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
Kiesewetter B; Troch M; Mayerhoefer ME; Dolak W; Simonitsch-Klupp I; Raderer M
Oncologist; 2016 Jan; 21(1):72-5. PubMed ID: 26621040
[TBL] [Abstract][Full Text] [Related]
6. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients.
Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Makita S; Fukuhara S; Munakata W; Maruyama D; Kobayashi Y; Tobinai K
Br J Haematol; 2016 Sep; 174(6):923-31. PubMed ID: 27460179
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Yang DY; Ren JH; Guo XN; Guo XL; Cai XY; Guo XF; Zhang JN
Genet Mol Res; 2015 Oct; 14(4):13588-94. PubMed ID: 26535672
[TBL] [Abstract][Full Text] [Related]
9. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.
Streubel B; Ye H; Du MQ; Isaacson PG; Chott A; Raderer M
Oncology; 2004; 66(6):476-80. PubMed ID: 15452377
[TBL] [Abstract][Full Text] [Related]
10. t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement.
Kuo SH; Cheng AL; Lin CW; Hsu CH; Wu MS; Yeh KH; Tzeng YS; Chen LT
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1387-95. PubMed ID: 21465313
[TBL] [Abstract][Full Text] [Related]
11. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.
Raderer M; Traub T; Formanek M; Virgolini I; Osterreicher C; Fiebiger W; Penz M; Jäger U; Pont J; Chott A; Kurtaran A
Br J Cancer; 2001 Nov; 85(10):1462-6. PubMed ID: 11720429
[TBL] [Abstract][Full Text] [Related]
13. Increased plasmacytic differentiation in gastric mucosa-associated lymphoid tissue lymphomas: Helicobacter pylori eradication response and IgG4+ plasma cell association.
Park S; Ahn S; Hong M; Ko YH
Hum Pathol; 2017 Jan; 59():113-119. PubMed ID: 27697589
[TBL] [Abstract][Full Text] [Related]
14. [Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].
Li BZ; Zhou XY; Ye HT; Yang WT; Fan YZ; Lu HF; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2007 Dec; 36(12):819-24. PubMed ID: 18346354
[TBL] [Abstract][Full Text] [Related]
15. Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.
Penz MZ; Fiebiger WC; Valencak JB; Osterreicher C; Ba-Ssalamah A; Formanek M; Brodowic T; Chott A; Raderer M
Anticancer Res; 2001; 21(4B):3049-52. PubMed ID: 11712809
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
18. PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lymphoid hyperplasia.
Goyal A; Moore JB; Gimbel D; Carter JB; Kroshinsky D; Ferry JA; Harris NL; Duncan LM
J Cutan Pathol; 2015 Jan; 42(1):6-15. PubMed ID: 25384543
[TBL] [Abstract][Full Text] [Related]
19. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
[TBL] [Abstract][Full Text] [Related]
20. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
